Outcomes of subsequent anti-lymphoma therapies after second-line axicabtagene ciloleucel or standard of care in ZUMA-7

医学 内科学 随机对照试验 化疗 免疫疗法 肿瘤科 淋巴瘤 无进展生存期 外科 胃肠病学 癌症
作者
Armin Ghobadi,Javier Muñoz,Jason R. Westin,Frederick L. Locke,David B. Miklos,Aaron P. Rapoport,Miguel‐Angel Perales,Patrick M. Reagan,Joseph P. McGuirk,Caron A. Jacobson,Marie José Kersten,Irit Avivi,Andrew C. Peng,Marco Schupp,Christina To,Olalekan O. Oluwole
出处
期刊:Blood Advances [Elsevier BV]
卷期号:8 (11): 2982-2990 被引量:1
标识
DOI:10.1182/bloodadvances.2023011532
摘要

Abstract The optimal management of patients with relapsed/refractory large B-cell lymphoma (LBCL) after disease progression or lack of response to second-line (2L) therapy remains unclear. Here, we report outcomes among patients who received subsequent antilymphoma therapy per investigator discretion separately by their randomized 2L arm in ZUMA-7, namely axicabtagene ciloleucel (axi-cel) vs standard of care (SOC). Progression-free survival (PFS) and overall survival (OS) were calculated from 3L therapy initiation. In the SOC arm, 127 of 179 randomized patients (71%) received 3L therapy. Median PFS among those who received 3L cellular immunotherapy (n = 68) vs those who did not (n = 59) was 6.3 vs 1.9 months, respectively; median OS was 16.3 vs 9.5 months, respectively. In the axi-cel arm, 84 of 180 randomized patients (47%) received 3L therapy. Median PFS among those who received 3L chemotherapy (n = 60) vs cellular immunotherapy (n = 8) was 1.7 vs 3.5 months, respectively; median OS was 8.1 months vs not reached, respectively. Of the 60 patients who received 3L chemotherapy, 10 underwent stem cell transplantation (SCT) after salvage chemotherapy. Median PFS was 11.5 vs 1.6 months, and median OS was 17.5 vs 7.2 months for those who did vs did not reach SCT, respectively. Eight patients received 3L cellular immunotherapy after 2L axi-cel. Of these, 6 patients received subsequent SCT in any line; all 6 were alive at data cutoff. These findings help inform subsequent treatment choices after 2L therapy failure for relapsed/refractory LBCL. The trial was registered at www.clinicaltrials.gov as #NCT03391466.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
故意的严青完成签到,获得积分10
1秒前
2秒前
浮游应助kasumi采纳,获得10
3秒前
3秒前
浮游应助科研通管家采纳,获得10
4秒前
4秒前
英俊的铭应助科研通管家采纳,获得10
4秒前
CipherSage应助科研通管家采纳,获得10
4秒前
FashionBoy应助科研通管家采纳,获得10
4秒前
浮游应助科研通管家采纳,获得10
4秒前
浮游应助科研通管家采纳,获得10
4秒前
4秒前
李健应助科研通管家采纳,获得10
4秒前
小二郎应助科研通管家采纳,获得10
5秒前
浮游应助科研通管家采纳,获得10
5秒前
Orange应助科研通管家采纳,获得10
5秒前
打打应助科研通管家采纳,获得10
5秒前
5秒前
bkagyin应助科研通管家采纳,获得10
5秒前
5秒前
5秒前
5秒前
6秒前
路过蜻蜓完成签到,获得积分10
7秒前
来活发布了新的文献求助10
7秒前
木叶发布了新的文献求助10
8秒前
9秒前
10秒前
14秒前
周苗发布了新的文献求助10
14秒前
开放凡桃发布了新的文献求助10
16秒前
科研菜鸡发布了新的文献求助10
17秒前
17秒前
jjdbqml发布了新的文献求助10
18秒前
士心完成签到,获得积分10
19秒前
20秒前
sherry完成签到 ,获得积分10
21秒前
23秒前
24秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Zeolites: From Fundamentals to Emerging Applications 1500
Architectural Corrosion and Critical Infrastructure 1000
Early Devonian echinoderms from Victoria (Rhombifera, Blastoidea and Ophiocistioidea) 1000
Hidden Generalizations Phonological Opacity in Optimality Theory 1000
2026国自然单细胞多组学大红书申报宝典 800
Research Handbook on Corporate Governance in China 800
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 内科学 生物化学 物理 计算机科学 纳米技术 遗传学 基因 复合材料 化学工程 物理化学 病理 催化作用 免疫学 量子力学
热门帖子
关注 科研通微信公众号,转发送积分 4908817
求助须知:如何正确求助?哪些是违规求助? 4185340
关于积分的说明 12997527
捐赠科研通 3952209
什么是DOI,文献DOI怎么找? 2167333
邀请新用户注册赠送积分活动 1185867
关于科研通互助平台的介绍 1092390